10-K · March 9, 2026
Boundless Bio remains a pre-revenue, clinical-stage oncology company focused on ecDNA-directed therapeutics (ecDTx). The company initiated a first-in-human Phase 1 KOMODO-1 trial of lead candidate BBI-940 in February…
Earnings analysis · 10-Q
BOLD earnings analysis
Filed May 8, 2026 · Our reading of the company's report
The latest report
Boundless Bio reported a net loss of $13.6 million for Q1 2026, an improvement from a $15.8 million net loss in Q1 2025, indicating a positive trend in cost management. Operating expenses decreased, driven primarily by…
Read full summary
Boundless Bio reported a net loss of $13.6 million for Q1 2026, an improvement from a $15.8 million net loss in Q1 2025, indicating a positive trend in cost management. Operating expenses decreased, driven primarily by lower R&D expenses. The company's focus on the BBI-940 program signals future potential despite ongoing losses.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.6
What stood out
-
Reduced Net Loss
Net loss improved to $13.6 million from $15.8 million year-over-year.
-
Lower R&D Expenses
R&D expenses decreased by $2.4 million to $9.7 million compared to Q1 2025.
-
Improved Operating Expenses
Total operating expenses fell to $14.5 million from $17.3 million, a decrease of $2.9 million.
-
Cash Position Remains Strong
Cash, cash equivalents, and short-term investments stand at $92.8 million as of March 31, 2026.
-
Initiated KOMODO-1 Trial
The company commenced the Phase 1 KOMODO-1 trial for BBI-940 in February 2026.
-
Future Cash Runway Extended
Current cash runway is projected to last into the second half of 2028.
What to watch
-
Accumulated Deficit
Accumulated deficit reached $273.2 million as of March 31, 2026.
-
Dependency on Clinical Trials
The company has not generated any revenue and remains reliant on successful clinical trial outcomes.
-
Need for Additional Funding
Future operations will require additional funding, with no committed sources of capital identified.
Management's outlook
Outlook deferred to future earnings call.
Earlier filings 4
10-Q · November 5, 2025
Boundless Bio reported no revenue for Q3 2025 and a narrower net loss of $13.9M (EPS -$0.62) versus a loss of $16.5M (EPS -$0.74) in the prior-year quarter. Operating expenses fell 19% year-over-year to $15.1M driven by…
10-Q · August 5, 2025
Boundless Bio remains pre-revenue but showed modest operating improvement in Q2 2025: quarterly net loss narrowed to $15,675 (three months ended June 30, 2025) from $16,976 a year earlier and EPS improved to $(0.70)…
10-Q · May 9, 2025
Boundless Bio remains a pre-revenue clinical-stage company with $138.3M of cash, cash equivalents and short-term investments as of March 31, 2025 and management believes that amount is sufficient to fund operations for…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.